The Distance Between Research and Reality: Neuropsychiatric Complexities in Patients with Dementia in Real-World Clinic Settings

Ruth Morin,Aaron Ritter,Amy Byers

DOI: https://doi.org/10.1016/j.jagp.2024.01.078

2024-04-01

Abstract:This session will highlight the gaps between research and clinical settings when treating patients with neuropsychiatric symptoms of dementia, particularly in the era of new biologic agents for disease modification. The research presented here will highlight the complexities in considering newly approved treatments for a general clinic population, relative to typical clinical trial exclusion criteria, particularly when it comes to comorbid psychiatric conditions. Additionally, epidemiology of neuropsychiatric conditions and suicide-specific factors in a national sample of older adults with dementia will be presented, with implications for assessment and intervention. First, Dr. Ritter will present a of clinical considerations for infusion-based therapies recently approved for the treatment of early-stage Alzheimer's disease (AD). He will focus on clinical trial inclusion/exclusion criteria, and the impact of these criteria on the selection sample for these agents in the testing and approval process. Specifically, Dr. Ritter will highlight the differences between typical clinical trial sample and the real-world clinic setting, particularly as it relates to neuropsychiatric comorbidity, and associated unknown risks associated with prescribing these agents for many dementia patients. Next, Dr. Morin will present an overview of typical neuropsychiatric symptoms coinciding with common neurodegenerative conditions with discussion of considerations for differential diagnosis, management, and treatment of dementia and dementia-related behaviors. She will then review the prevalence of psychiatric comorbidity in a national sample of older patients with common subtypes of dementia seen in Veterans Health Administration (VHA) care settings, highlighting the significant multimorbidity and challenges of caring for this high-risk population. Finally, Dr. Byers will discuss the epidemiology of suicide in dementia among older patients using VHA health services. She will provide an overview of suicide and suicide-related behaviors in this population, as well as considerations related to risk assessment and intervention. In addition, Dr. Byers will present data about the significance of timing (recency) of neurocognitive diagnosis as well as subtype of dementia that may be associated with heightened risk of suicide attempt.

psychiatry,geriatrics & gerontology,gerontology